Company History: Wacker Biotech GmbH
||The state-owned Gene Technology Pilot Plant (GPA) starts operations at the Central Institute for Microbiology and Experimental Therapy (ZIMET) on the Beutenberg Campus in Jena. Focus on bioprocess development for the production of biopharmaceuticals in recombinant microorganisms.
||The GPA develops a high-cell-density fermentation process in E. coli, later patented and marketed as WACKER’s DENSETEC® technology.
||Inception of the state-owned Hans Knöll Institute (HKI) on the Beutenberg Campus in Jena. The GPA becomes a department of the HKI.
||The HKI (GPA) is granted GMP manufacturing authorization for the production of a recombinant protein therapeutic for clinical trials.
||Inception of the company ProThera GmbH on the Beutenberg Campus in Jena, as spin-off of the HKI and direct successor of the GPA. Focus on GMP-compliant contract manufacturing of therapeutic proteins in microorganisms.
||Wacker Chemie AG takes over ProThera GmbH. The company is renamed Wacker Biotech GmbH.
Inception of the company Scil Proteins Production GmbH on the Weinberg Campus in Halle (Saale). Focus on GMP-compliant contract manufacturing of therapeutic proteins in microorganisms.
||Market launch of ESETEC®, WACKER’s innovative E. coli secretion technology for the cost-effective production of therapeutic proteins.
||Scil Proteins Production GmbH opens GMP facility in Halle. The facility has 1,500-liter upstream capacity and matching downstream equipment. Expertise in protein refolding.
||Construction of a new warehouse and a new laboratory and administration building on the Beutenberg Campus site in Jena.
||Complete reconstruction and extension of the production building (former GPA building) in Jena according to current GMP requirements.
||Scil Proteins Production receives EMA approval for the commercial production of Reteplase (trade names Rapilysin®/Retavase®).
||Wacker Biotech acquires Scil Proteins Production GmbH, thus doubling its capacity for process development and production, and adds substantial refolding expertise to the technology portfolio.
||WACKER takes over SynCo Bio Partners Luxembourg S.à r.l., the pharmaceutical facility for microbial GMP production in the Netherlands, which has been operating under the name Wacker Biotech B.V. since November. The site in Amsterdam is acquired for the manufacture of biopharmaceuticals, live microbial products and vaccines, as well as the associated business.